Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries

Amayelle Rey1,2 | Valérie Gras-Champel1,2 | Gabriel Choukroun2,3 | Kamel Masmoudi1 | Sophie Liabeuf1,2

1Division of Clinical Pharmacology, Amiens University Hospital, Amiens, France
2MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France
3Division of Nephrology, Amiens University Hospital, Amiens, France

Correspondence
Sophie Liabeuf, Division of Clinical Pharmacology, Amiens University Hospital, Avenue René Laennec, F-80000 Amiens, France.
Email: liabeuf.sophie@chu-amiens.fr

Abstract
Drugs constitute one of the leading causes of acute kidney injuries (AKIs) and can appear in community (CA-AKI) or hospital (HA-AKI) population. The objectives of the present study of a cohort of hospitalized patients with AKI were to describe the characteristics of drug-induced AKIs and the patients’ short-term outcomes and assess risk factors for drug-induced AKIs overall, CA-AKIs, and HA-AKIs. Based on a cohort of 1557 hospitalized patients suffering from AKIs based on PMSI extraction and chart review (IRA-PMSI), drug-induced AKIs were identified by applying the Naranjo adverse drug reaction (ADR) probability scale. Multivariate logistic regression was used to identify factors associated with CA-AKIs and/or HA-AKIs. When considering the 1557 patients who experienced an AKI, 445 (28.6%) of the injuries were drug-induced (180 CA-AKIs (40.4%) and 265 HA-AKIs (59.6%)). Antibiotics, diuretics, and contrast agents were significantly more likely to be involved in HA-AKIs, whereas antineoplastic, lipid-lowering drugs, antidiabetics, and immunosuppressive were significantly more likely to be involved in CA-AKIs. Female sex (odds ratio [OR] [95%CI] = 1.3 [1.04–1.67]), chronic kidney disease (CKD) (OR = 1.8 [1.40–2.67]), and a history of ADRs of any type (OR = 1.3 [1.05–1.73]) were significant risk factors for drug-induced AKIs. CKD was a risk factor for both CA-AKI and HA-AKI. In view of the long-term impact of AKI on the kidneys and the differences between our CA-AKI and HA-AKI subgroups, our present results are interesting for optimizing treatments, limiting the occurrence of CA- and HA-AKIs and (ultimately) reducing healthcare costs.

KEYWORDS
acute kidney injury, community- and hospital-acquired, drug-induced, pharmacovigilance, PMSI, risk factors

1 | INTRODUCTION

Acute kidney injury (AKI) is a common, treatable, reversible syndrome that can be immediately life-threatening and can have serious long-term consequences [1]. The main impact is on the kidney itself: the development of chronic kidney disease (CKD), accelerated progression to end-stage renal disease (ESRD), and failure to recover kidney function [2, 3]. The risk factors for AKI have been well studied; they include older age, female...
sex, high body mass index (BMI), a history of hypertension, cardiovascular disease (CVD), diabetes, CKD, and previous AKI [4–6]. Based on a cohort of hospitalized patients suffering from AKIs based on PMSI extraction and chart review (IRA-PMSI), we have recently described different characteristics between hospital-acquired AKI (henceforth referred to as HA-AKI) and community-acquired AKI (henceforth referred to as CA-AKI). Drug-induced AKIs accounted for 28.6% of the AKIs [7]. Indeed, the main avoidable risk factor is the use of certain medications [8, 9].

Medications constitute one of the leading causes of AKI [10] and the third to fifth leading cause of hospital-acquired AKI [11]. According to the meta-analysis by Cartin-Ceba et al., each additional nephrotoxic drug increases the risk of developing AKI by 53% [5]. Jacobs et al.’s systematic review showed that iatrogenic AKIs now account for 55–75% of the patients with AKI admitted to intensive care units (ICUs) [12]. Several studies have assessed the role of nephrotoxic drugs, including antibiotics (particularly aminoglycosides, amphotericin, and glycopeptides), immunosuppressive drugs (such as cyclosporine), renin-angiotensin drugs, contrast agents, non-steroidal anti-inflammatory drugs (NSAIDs), and diuretics [10, 13–16]. Various physiopathological mechanisms are involved in drug nephrotoxicity: impaired glomerular filtration, tubular cell toxicity, interstitial nephritis, crystal nephropathy [15, 16]. A single drug class may even be responsible for several types of damage [17]. Risk factors for drug-induced AKI described in the literature include a history of diabetes, hypertension [18], and adverse drugs reactions (ADRs) [19]. Drug-induced AKI has been particularly studied in ICUs, due to the number of drugs administered to patients in this medical unit (twice as much as in other departments) and the nephrotoxicity of many of these drugs [11, 20].

Drug-induced HA-AKI is a common problem; in a cross-sectional survey conducted in mainland China, it accounted for 37.5% of all hospital-acquired AKIs [21]. Robert et al. reported that drug-induced CA-AKI accounted for 58.8% of all CA-AKIs [8]. Although CA-AKI accounts for a non-negligible proportion of hospital admissions, it has been less extensively studied than HA-AKI. To the best of our knowledge, few studies have compared drug-induced community- and hospital-acquired AKI.

The objectives of the present study of a cohort of hospitalized patients with AKI were to describe the characteristics of drug-induced AKIs and the patients’ short-term outcomes and assess risk factors for drug-induced AKIs overall, CA-AKIs, and HA-AKIs.

2 | MATERIALS AND METHODS

This study was conducted in a university hospital (Amiens Picardie University Hospital). In 2019, this hospital had 1664 beds and places, including 1238 in medicine, surgery, and obstetrics wards. A total of 60 134 patients were admitted during this year, including 289 to the transplantation unit (82 for kidney transplantation), 2566 to the cardiothoracic surgery unit, 787 to the ICUs, and 1285 to the nephrology department.

2.1 | Data source: Cohort of hospitalized patients with drug-induced AKIs

A single-center retrospective study (“IRA-PMSI”) from January 1, 2019, to June 30, 2019, was performed to build a cohort of hospitalized patients suffering from AKIs based on PMSI extraction and chart review. The IRA-PMSI study’s objectives and procedures were approved by an independent ethics committee (CPP Nord Ouest II, Amiens, France; reference: RCB 2020-A00556-33), and the study was registered at ClinicalTrials.gov (NCT04923750). The primary objective of the IRA-PMSI study was to assess the ability of several ICD-10 codes to identify AKIs. Results have already been published, such as description of the patient’s selection which we described in the Data S1 [7]. The present report describes one of the IRA-PMSI study’s secondary objectives: to describe the characteristics of drug-induced AKIs and to assess their risk factors.

2.2 | Definition of drug-induced AKI

In order to determine whether a given AKI identified with our algorithm (Figure S1) was drug-induced or not, a pharmacist with expertise in pharmacovigilance and pharmacology (employed at the Amiens Regional Pharmacovigilance Centre) applied the Naranjo ADR probability scale to each drug delivered in hospital in the 48 h before the AKI [22]. This validated tool is mainly used to probe the causal nature of relationships between drug and adverse event through 10 questions on the event’s chronology, symptom profile, and literature data [23]. After calculation of the total Naranjo score, each drug was assigned to one of the following probability categories: definite ≥ 9, probable 5–8, possible 1–4, and doubtful ≤ 0. The pharmacovigilance expert considered that the drug was imputed for AKI that if the score category was “possible,” “probable,” or “definite” (i.e., any score other than 0). For 100 randomly selected drug prescriptions, another pharmacovigilance expert applied the Naranjo scale; the correlation between the two expert’s scores was good. The candidate drugs’ Anatomical Therapeutic Chemical (ATC) classes were recorded. By applying our algorithm (Figure S1), drug-induced AKIs were classified as CA-AKIs or HA-AKIs.
2.3 Clinical and demographic information

For each identified AKI, we collected several clinical and demographic information from the patients’ EMRs. The demographic variables included age, sex, and BMI. The comorbidities considered as risk factors for AKI were hypertension, diabetes, dyslipidaemia, heart disease, cancer, gout, CKD (stage ≤3A, [estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m²], 3B [eGFR between 30 and 44 mL/min/1.73 m²], 4 [eGFR between 15 and 29 mL/min/1.73 m²], or 5 and not on dialysis [eGFR <15 mL/min/1.73 m²]), nephrectomy, kidney transplant, previous AKI, and a history of ADRs. Lastly, clinical data related to the episode of AKI were gathered: the medical unit, KDIGO grade, length of hospital stay, use of dialysis or not, and outcome.

2.4 Statistics

Descriptive statistics were used to characterize the study population. Patients were divided according to whether the AKI was drug-induced or not and then whether the injury was acquired in the community or in hospital. Groups were compared using a chi-squared test or Fisher’s test, depending on the data distribution.

The prescription drugs administered to patients with CA-AKI versus HA-AKI were assessed using a chi-squared test or Fisher’s test.

To compare drug-induced AKIs with non-drug-induced AKIs, we calculated the crude odds ratio (OR) [95% confidence interval (CI)] and the P value. Next, we used multivariate logistic regression to model the relationship between risk factors and drug-induced AKI, by taking the non-drug-induced AKI group as a reference. The potential adjustment variables were age, sex, obesity (defined as a BMI ≥ 30 kg/m²), and risk factors for AKI (i.e., hypertension, diabetes, dyslipidaemia, heart disease, cancer, gout, CKD, nephrectomy, kidney transplant, previous AKI, and a history of ADRs). To optimize the model’s fit, we used a parsimonious model that included all variables with P < 0.2 in a univariate analysis or contextual interest.

In a secondary analysis, the above-mentioned values were calculated for the CA-AKI and HA-AKI subgroups (relative to the non-drug-induced AKI group). Likewise, same variables were used to determine the crude OR [95%CI] (i.e., age, sex, obesity, and risk factors for AKI). Lastly, the multivariate logistic regression model included all the variables with P < 0.2 in a univariate analysis or contextual interest.

The threshold for statistical significance was set to P < 0.05. All analyses were performed using R software (version 3.6.0, R Foundation for Statistical Computing, Vienna, Austria) [24].

3 RESULTS

3.1 Characteristics of the study population

Between January 1, 2019, and June 30, 2019, 3479 of the patients admitted to Amiens-Picardie University Hospital had two creatinine measurements (Figure 1);
2473 patients (773 with exclusion criterion and 233 with duplicate hospital stay) represented the study population included; 1557 of the 2473 patients had experienced an AKI. Most episodes of AKI were identified from both the EMR review and the laboratory results (54.8%); a lower proportion (33.1%) were only physician-diagnosed (Table S1). In the AKI population, the mean age (standard deviation (SD)) was 71.3 (15.1), and 45.7% were women (Table 1).

3.2 | Characteristics of drug-induced AKIs

Of the 1557 AKIs, 445 (28.6%) were drug-induced (Table 1). The mean (SD) age of patients with a drug-induced AKI was 72.1 (14.6). The patients’ characteristics are summarized in Table 1. Relative to patients with a non-drug-induced AKI, patients with a drug-induced AKI were significantly more likely to be women (43.6% vs. 51.0%, respectively), to be obese (6.6% vs. 6.9%), and to have comorbidities. Drug-induced AKIs were significantly more likely to have a favorable outcome (in 69.9% of patients vs. 65.7% of patients with non-drug-induced AKI) but were also more likely to lead to the onset or progression of CKD (19.8% vs. 13.7%, respectively). Drug-induced AKIs were more likely to be managed in the nephrology department, whereas non-drug-induced AKIs were more likely to be managed in the ICU (P < 0.001) (Table 2).

In drug-induced AKI, the mean (SD) number of involved drugs was 2.3 (1.7). A total of 1009 drugs were imputed with Naranjo scale (464 for CA-AKIs and 545 for HA-AKIs). The main ATC classes involved were diuretics (32.2%), renin-angiotensin drugs (17.3%), and antibiotics (7.8%) (Table 3). The main imputed antibiotic classes were penicillins (2.5%), sulfamides (1.3%), and fluoroquinolones (1.1%) (Table S2). The main specifically imputed drugs were furosemide (21.8%), spironolactone (5.8%), and ramipril (5.1%). For more details, see Table S3.

| TABLE 1 | Baseline characteristics of study participants, overall and according to the type of AKI (drug-induced or non-drug-induced) |
|-----------------|---------------------------------------------------------------|
| Demographics   |                                                                 |
| Age, y, mean (SD) | 71.3 (15.1) | 72.1 (14.6) | 71.0 (15.3) | 0.23 |
| Women, n (%)    | 712 (45.7) | 227 (51.0) | 485 (43.6) | <0.001* |
| BMI, kg/m², mean (SD) | 27.7 (6.7) | 28.8 (6.9) | 27.3 (6.6) | <0.001* |
| Obesity (BMI ≥30 kg/m²), n (%) | 461 (29.6) | 153 (34.4) | 308 (27.7) | <0.001* |
| Comorbidities   |                                                                 |
| CKD, n (%)      | 445 (28.6) | 180 (40.4) | 265 (23.8) | <0.001* |
| CKD stage       |                                                                 |
| ≤3A (≥45 mL/min/1.73 m²) | 215 (13.8) | 79 (17.8) | 136 (12.2) | <0.001* |
| 3B (30–44 mL/min/1.73 m²) | 148 (9.5) | 66 (14.8) | 82 (7.4) | <0.001* |
| 4 (15–29 mL/min/1.73 m²) | 73 (4.7) | 33 (7.4) | 40 (3.6) | <0.001* |
| 5 (<15 mL/min/1.73 m²) (not on dialysis) | 9 (0.6) | 2 (0.4) | 7 (0.6) | <0.001* |
| Hypertension, n (%) | 1092 (70.1) | 340 (76.4) | 752 (67.6) | <0.001* |
| Diabetes, n (%) | 544 (35.0) | 176 (39.6) | 368 (33.1) | 0.016* |
| Dyslipidaemia    | 569 (36.5) | 194 (43.6) | 375 (33.7) | <0.001* |
| History of CVD, n (%) | 757 (48.6) | 250 (56.2) | 507 (45.6) | <0.001* |
| Gout, n (%)      | 112 (7.2) | 39 (8.8) | 73 (6.6) | 0.13 |
| Cancer, n (%)    | 456 (29.3) | 136 (30.6) | 320 (28.8) | 0.48 |
| History of kidney transplant, n (%) | 49 (3.1) | 20 (4.5) | 29 (2.6) | 0.05 |
| History of nephrectomy, n (%) | 91 (5.8) | 31 (7.0) | 60 (5.4) | 0.23 |
| History of AKI, n (%) | 242 (15.5) | 93 (20.9) | 149 (13.4) | <0.001* |
| History of ADRs, n (%) | 439 (28.2) | 156 (35.1) | 283 (25.4) | <0.001* |

Note: The “history of ADRs” item included ADRs that occurred before the episode of AKI and were mentioned in the patient’s EMRs. Quantitative variables are quoted as the mean (standard deviation), and qualitative variables are quoted as the frequency (percentage).

Abbreviations: ADR, adverse drug reaction; AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease. Statistically significant differences are shown in bold type.

*In Wilcoxon’s test or a chi-squared test, for patients with drug-induced AKI versus patients with non-drug-induced AKI.

According to the patients’ medical records.

Statistically significant.
An adjusted multivariate logistic regression identified several significant risk factors for drug-induced AKI: female sex (OR [95% CI] = 1.3 [1.04–1.67]), CKD (1.8 [1.40–2.67]), and a previous ADR (1.3 [1.05–1.73]) (Table 4).

### 3.3 | Comparison of HA-AKIs and CA-AKIs

Of the 445 drug-induced AKIs, 180 (40.4%) were classified as CA-AKIs, and 265 (59.6%) were classified as HA-AKIs (Table 3). In both subgroups, the most frequently involved drugs were diuretics (25.6% for CA-AKI and 37.8% for HA-AKI) and renin-angiotensin drugs (18.8% for CA-AKI and 16.1% for HA-AKI). For more details, see Table 3.

Antibiotic, diuretics, and contrast agents were significantly more likely to be involved in HA-AKI, whereas antineoplastic, lipid-lowering drugs, antidiabetics, and immunosuppressive agents were significantly more likely to be involved in CA-AKI (Table 3).

CKD was a significant risk factor in both subgroups (OR [95% CI] = 1.9 [1.22–2.82]) for CA-AKI and 1.8 [1.29–2.58] for HA-AKI). Female sex was a risk factor for CA-AKI only (Tables 5 and 6).

### 4 | DISCUSSION

Our study of hospitalized patients with AKI highlighted the high proportion (28.6%) of patients with drug-induced AKI. Our comprehensive analysis of determinants of drug-induced AKI enabled us to identify female sex, CKD, and a history of ADRs as risk factors in this population. The comparison between CA-AKI and HA-AKI drug-induced highlights that patient characteristics, drugs, and the issues are not the same and that the key messages are different. Indeed, general practitioners and clinicians should be more cautious when prescribing these drugs—especially in at-risk patients such as those with CKD.

The proportion of drug-induced AKIs in our cohort (28.6%) was slightly higher than in the epidemiological literature (between 14.4% and 20.0%, depending on the study [11, 25, 26]). This disparity with the literature data might be to the relatively advanced age of our study population (mean age: 71.3). Age is a well known...
risk factor for AKI [27]: The risk of developing AKI is 3.5 times greater in patients aged over 65 or 70 than in younger patients [28, 29]. Moreover, AKIs often have several causes and are aggravated by CKD, cardiovascular morbidities, and polypharmacy. Robert et al. showed that 63.2% of community-acquired drug-induced AKIs had several contributory factors [8].

The main drugs involved in AKIs in our study were similar to those mentioned in the literature. It is well known that diuretics and angiotensin-converting enzyme inhibitors are frequently involved in AKI [10]. By decreasing the synthesis of angiotensin II, angiotensin-converting enzyme inhibitors alter intraglomerular haemodynamics and thus decrease the GFR. This hemodynamic disorder may result in nephrotoxicity—especially in cases of reduced renal blood flow [15, 17]. The role of loop diuretics in AKI is subject to debate. These drugs are prescribed frequently in emergency and intensive care medicine for the treatment of congestive heart failure, since they enable the elimination of large amounts of electrolytes and water if the kidneys are still able to filter. As also reported in the literature, the most frequently prescribed drug in our study was furosemide. However, AKIs with various aetiologies are characterized by a low GFR [30]. According to a multicentre prospective study conducted in Shanghai, diuretics were responsible for 22.2% of all drug-induced AKIs [31]. Diuretics may reduce glomerular filtration—leading to functional AKI—and can also induce acute interstitial nephritis via an immunoallergic mechanism [15].

Using the Naranjo scale for ADRs, we found that CA-AKIs and HA-AKIs involved different ATC classes. Antibiotic, diuretics, and contrast agents were significantly more likely to be involved in HA-AKI, which is in line with the literature data [21]. This might be due to the AKI’s etiology: Radiological examinations and the management of sepsis and CVD occur in hospital and require the administration of these types of drug [32]. Antibiotics can induce AKI through several mechanisms [15].

Contrast agents have a direct nephrotoxic effect on tubular epithelial cells, with the release of vasoactive molecules, an increase in oxidative stress, and subsequent ischaemic renal cell injury [33].

Antineoplastic, antidiabetic, and immunosuppressive agents were significantly more frequently involved in CA-AKI. This might have been due to the characteristics of the affected population, such as a greater comorbidity burden and more frequent polypharmacy for chronic health conditions. Antineoplastic agents can produce chronic interstitial injury by inducing oxidative stress, apoptosis, necrosis, local and systemic inflammation, the release of inflammatory mediators, and

| Table 3: Main drug classifications involved in drug-induced AKI |
|---------------------------------------------------------------|
| All drug-induced AKIs (n = 445)                              |
| CA drug-induced AKI (n, %) n = 180 (40.4)                     |
| HA-drug-induced AKI (n, %) n = 265 (59.6)                     |
| **P value**                                                  |
| Number of drugs (mean, SD)                                  |
|                                      2.3 (1.7)        | 2.6 (1.7)        | 3.0 (1.5)        | <0.001*  |
| ATC (n, %)                                                   |
| Diuretics                                                   |
| Renin-angiotensin drugs                                       |
| Antibacterial agents for systemic use                        |
| Antineoplastic agents                                        |
| Antibiotics, except insulin                                  |
| Psycholeptics                                               |
| Contrast agents                                             |
| Analgesics                                                  |
| Immunosuppressive agents                                     |
| Beta-blockers                                               |
| Lipid-lowering agents                                        |
| NSAIDs                                                      |
| Calcium channel blockers                                     |
| Anti-gout drugs                                              |
| **Number of drugs (mean, SD)**                              |
|                                      2.3 (1.7)        | 2.6 (1.7)        | 3.0 (1.5)        | <0.001*  |
| ATC (n, %)                                                   |
| Diuretics                                                   |
| Renin-angiotensin drugs                                       |
| Antibacterial agents for systemic use                        |
| Antineoplastic agents                                        |
| Antibiotics, except insulin                                  |
| Psycholeptics                                               |
| Contrast agents                                             |
| Analgesics                                                  |
| Immunosuppressive agents                                     |
| Beta-blockers                                               |
| Lipid-lowering agents                                        |
| NSAIDs                                                      |
| Calcium channel blockers                                     |
| Anti-gout drugs                                              |
| **Number of drugs (mean, SD)**                              |
|                                      2.3 (1.7)        | 2.6 (1.7)        | 3.0 (1.5)        | <0.001*  |
| ATC (n, %)                                                   |
| Diuretics                                                   |
| Renin-angiotensin drugs                                       |
| Antibacterial agents for systemic use                        |
| Antineoplastic agents                                        |
| Antibiotics, except insulin                                  |
| Psycholeptics                                               |
| Contrast agents                                             |
| Analgesics                                                  |
| Immunosuppressive agents                                     |
| Beta-blockers                                               |
| Lipid-lowering agents                                        |
| NSAIDs                                                      |
| Calcium channel blockers                                     |
| Anti-gout drugs                                              |
| **Number of drugs (mean, SD)**                              |
|                                      2.3 (1.7)        | 2.6 (1.7)        | 3.0 (1.5)        | <0.001*  |

Note: Quantitative variables are quoted as the mean (standard deviation), and qualitative variables are quoted as the frequency (percentage).

Abbreviations: AKI, acute kidney injury; CA, community-acquired; HA, hospital-acquired; NSAID, non-steroidal anti-inflammatory drug; SD, standard deviation.

*Statistically significant differences are shown in bold type.

Statistically significant.

*Statistically significant.
Immuno-suppressive drugs may induce acute tubular necrosis, chronic interstitial nephritis, and thrombotic microangiopathy [15]. Drug-induced AKIs are often avoidable [8, 35]. Given that different types of medication are involved in CA-AKI and HA-AKI, it might be possible to adjust and improve the management of these injuries as a function of the affected population. In hospital, the dose level of diuretics (like furosemide) should be adjusted according to the individual patient’s diuresis rate and comorbidities [36]. Various ways of preventing contrast-induced AKI have been documented, and the guidelines have been updated [37]: increase hydration in patients with CKD, initiate prophylaxis with intravenous

### TABLE 4

The regression model for the risk of drug-induced AKI ($N = 445$)

| Predictors          | Crude OR [95% CI] | $P$ value | Adjusted OR [95% CI]$^a$ | Adjusted $P$ value$^a$ |
|---------------------|-------------------|-----------|--------------------------|------------------------|
| **Demographics**    |                   |           |                          |                        |
| Age, y, mean (SD)   | 1.0 [0.99–1.01]   | 0.23      | 0.99 [0.98–1.01]         | 0.57                   |
| **Sex**             |                   |           |                          |                        |
| Male                | Reference         |           | Reference                |                        |
| Female, n (%)       | 1.3 [1.01–1.68]   | $<0.001^*$| 1.3 [1.04–1.67]          | 0.016$^*$              |
| **Obesity**         |                   |           |                          |                        |
| BMI < 30 kg/m²      | Reference         |           | Reference                |                        |
| BMI ≥ 30 kg/m², n (%)| 1.4 [1.08–1.73]  | 9.05 e-3* | 1.2 [0.92–1.52]          | 0.20                   |
| **Comorbidities$^b$**|                   |           |                          |                        |
| **CKD**             |                   |           |                          |                        |
| No history of CKD   | Reference         |           | Reference                |                        |
| History of CKD      | 2.2 [1.72–2.74]   | $<0.001^*$| 1.8 [1.40–2.67]          | $<0.001^*$             |
| **Hypertension**    |                   |           |                          |                        |
| No hypertension     | Reference         |           | Reference                |                        |
| Hypertension        | 1.6 [1.21–2.00]   | $<0.001^*$| 1.2 [0.87–1.55]          | 0.31                   |
| **Diabetes**        |                   |           |                          |                        |
| No diabetes         | Reference         |           | Reference                |                        |
| Diabetes            | 1.3 [1.05–1.66]   | 1.58 e-2* | 0.97 [0.75–1.25]         | 0.81                   |
| **Dyslipidaemia**   |                   |           |                          |                        |
| No dyslipidaemia    | Reference         |           | Reference                |                        |
| Dyslipidaemia       | 1.5 [1.21–1.90]   | $<0.001^*$| 1.3 [0.99–1.63]          | 0.06                   |
| **History of CVD**  |                   |           |                          |                        |
| No history of CVD   | Reference         |           | Reference                |                        |
| History of CVD      | 1.5 [1.22–1.91]   | $<0.001^*$| 1.3 [0.99–1.61]          | 0.07                   |
| **History of gout** |                   |           |                          |                        |
| No history of gout  | Reference         |           | Reference                |                        |
| History of gout     | 1.4 [0.90–2.04]   | 0.13      | 1.0 [0.67–1.57]          | 0.87                   |
| **Kidney transplantation** |             |           |                          |                        |
| No history of kidney transplantation | Reference         |           | Reference                |                        |
| History of kidney transplantation | 1.8 [0.97–3.12] | 0.05      | 1.0 [0.55–1.94]          | 0.90                   |
| **History of AKI**  |                   |           |                          |                        |
| No history of AKI   | Reference         |           | Reference                |                        |
| History of AKI      | 1.7 [1.28–2.27]   | $<0.001^*$| 1.2 [0.87–1.62]          | 0.27                   |
| **History of ADRs** |                   |           |                          |                        |
| No history of ADRs  | Reference         |           | Reference                |                        |
| History of ADRs     | 1.6 [1.25–2.00]   | $<0.001^*$| 1.3 [1.05–1.73]          | $<0.001^*$             |

Note: Statistically significant differences are shown in bold type.
Abbreviations: ADRs, adverse drug reactions; AKI, acute kidney injury; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; OR, odds ratio.

$^a$Adjusted for variables with $P < 0.2$ in a univariate analysis or contextual interest.

$^b$According to the patients’ EMRs.

*Statistically significant.
saline and intravenous sodium bicarbonate, and withdraw nephrotoxic drugs before contrast agent are administered. The use of medication to reduce the oxidative stress induced by contrast agents has also been studied [38].

In the community, optimal hydration should be constantly encouraged and monitored in patients at risk of drug-induced AKI. This approach encompasses patient education and prescription policies. Combinations of nephrotoxic drugs should be avoided whenever possible and especially in patients with polypharmacy [11]. The use of over-the-counter medications should be checked and monitored, depending on the patient’s comorbidities (e.g., CKD) and prescription medications.

### TABLE 5 Regression model for risk of HA drug-induced AKI (n = 265)

| Predictors                          | Crude OR [95% CI] | P value | Adjusted OR [95% CI] | Adjusted P value |
|-------------------------------------|-------------------|---------|----------------------|------------------|
| **Demographics**                    |                   |         |                      |                  |
| Age, y, mean (SD)                   | 1.0 [1.00–1.02]   | 0.04*   | 1.0 [0.80–1.01]      | 0.79             |
| Sex                                 |                   |         |                      |                  |
| Men                                 | Reference         |         | Reference            |                  |
| Women, n (%)                        | 1.3 [0.99–1.76]   | 0.06    | 1.3 [0.94–1.74]      | 0.11             |
| **Obesity**                         |                   |         |                      |                  |
| BMI < 30 kg/m²                       | Reference         |         | Reference            |                  |
| BMI ≥ 30 kg/m², n (%)               | 1.3 [0.94–1.72]   | 0.12    | 1.1 [0.78–1.51]      | 0.60             |
| **Comorbidities**                   |                   |         |                      |                  |
| CKD                                 |                   |         |                      |                  |
| No history of CKD                   | Reference         |         | Reference            |                  |
| History of CKD                      | 2.2 [1.61–3.01]   | <0.001* | 1.8 [1.29–2.58]      | <0.001*          |
| Hypertension                        |                   |         |                      |                  |
| No hypertension                     | Reference         |         | Reference            |                  |
| Hypertension                         | 1.6 [1.13–2.18]  | 7.02 e-3 | 1.9 [0.75–1.59]      | 0.66             |
| Diabetes                            |                   |         |                      |                  |
| No diabetes                         | Reference         |         | Reference            |                  |
| Diabetes                            | 1.3 [0.96–1.75]   | 0.09    | 0.9 [0.66–1.31]      | 0.69             |
| Dyslipidaemia                        |                   |         |                      |                  |
| No dyslipidaemia                    | Reference         |         | Reference            |                  |
| Dyslipidaemia                        | 1.9 [1.41–2.52]   | <0.001* | 1.6 [1.20–2.28]      | <0.001*          |
| History of CVD                      |                   |         |                      |                  |
| No history of CVD                   | Reference         |         | Reference            |                  |
| History of CVD                      | 1.7 [1.25–2.24]   | <0.001* | 1.3 [0.92–1.76]      | 0.14             |
| Cancer                              |                   |         |                      |                  |
| No cancer                           | Reference         |         | Reference            |                  |
| With cancer                         | 0.8 [0.58–1.10]   | 0.18    | 0.9 [0.61–1.19]      | 0.36             |
| Kidney transplantation              |                   |         |                      |                  |
| No history of kidney transplantation| Reference         |         | Reference            |                  |
| History of kidney transplantation   | 2.0 [0.69–5.31]   | 0.18    | 1.1 [0.38–3.30]      | 0.80             |
| History of AKI                      |                   |         |                      |                  |
| No history of AKI                   | Reference         |         | Reference            |                  |
| History of AKI                       | 1.6 [1.08–2.32]   | 1.65 e-2* | 1.1 [0.74–1.68]    | 0.59             |
| History of ADRs                      |                   |         |                      |                  |
| No history of ADRs                  | Reference         |         | Reference            |                  |
| History of ADRs                      | 1.4 [1.06–1.99]   | 1.92 e-2* | 1.3 [0.93–1.80]    | 0.12             |
Our multivariate analysis identified several significant risk factors for drug-induced AKI: female sex, CKD, and previous ADR. These findings were consistent with the literature data [11]. A sex difference in ADRs has been well documented [39]; Moyer et al. found a 1.6-fold-greater OR in women than in men, for example [40]. Historically, women were less likely than men to be included in clinical trials. Moreover, it has been reported that specific physiological features of women (i.e., hormonal status) can alter the pharmacokinetics and pharmacodynamics of medications [40], and this influences the response to injury and/or treatment [41]. Indeed, Watson et al.’s post-marketing surveillance analysis of spontaneous reports in VigiBase

Table 6: The regression model for the risk of CA drug-induced AKI (N = 180)

| Demographics | Crude OR [95% CI] | P value | Adjusted OR [95% CI] | Adjusted P value |
|--------------|-------------------|---------|----------------------|------------------|
| Age, y, mean (SD) | 0.99 [0.98–1.01] | 0.57 | 0.99 [0.98–1.00] | 0.17 |
| Sex | Reference | Reference | Reference | Reference |
| Female, n (%) | 1.4 [0.98–1.96] | 0.07 | 1.5 [1.02–2.14] | 0.04* |
| Obesity | Reference | Reference | Reference | Reference |
| BMI < 30 kg/m² | Reference | Reference | Reference | Reference |
| BMI ≥ 30 kg/m², n (%) | 1.5 [1.05–2.25] | 2.51 e-2* | 1.3 [0.89–2.02] | 0.16 |

Comorbidities

| CKD | Crude OR [95% CI] | P value | Adjusted OR [95% CI] | Adjusted P value |
|---|-------------------|---------|----------------------|------------------|
| No history of CKD | Reference | Reference | Reference | Reference |
| History of CKD | 2.2 [1.52–3.11] | <0.001* | 1.9 [1.22–2.82] | <0.001* |
| Hypertension | Reference | Reference | Reference | Reference |
| No hypertension | Reference | Reference | Reference | Reference |
| Hypertension | 1.5 [1.04–2.30] | 3.52 e-2* | 1.2 [0.74–1.88] | 0.50 |
| Diabetes | Reference | Reference | Reference | Reference |
| No diabetes | Reference | Reference | Reference | Reference |
| With diabetes | 1.4 [0.96–1.93] | 0.09 | 1.0 [0.71–1.54] | 0.82 |
| History of CVD | Reference | Reference | Reference | Reference |
| No history of CVD | Reference | Reference | Reference | Reference |
| History of CVD | 1.4 [0.96–1.93] | 0.08 | 1.3 [0.86–1.89] | 0.23 |

Cancer

| Cancer | Crude OR [95% CI] | P value | Adjusted OR [95% CI] | Adjusted P value |
|---|-------------------|---------|----------------------|------------------|
| No cancer | Reference | Reference | Reference | Reference |
| Cancer | 1.7 [1.15–2.40] | 6.35 e-3* | 1.9 [1.29–2.79] | <0.001* |
| History of gout | Reference | Reference | Reference | Reference |
| No history of gout | Reference | Reference | Reference | Reference |
| History of gout | 1.7 [0.93–3.05] | 0.08 | 1.4 [0.75–2.67] | 0.27 |
| Kidney transplantation | Reference | Reference | Reference | Reference |
| No history of kidney transplantation | Reference | Reference | Reference | Reference |
| History of kidney transplantation | 1.7 [0.80–3.43] | 0.15 | 1.0 [0.45–2.24] | 0.96 |
| History of AKI | Reference | Reference | Reference | Reference |
| No history of AKI | Reference | Reference | Reference | Reference |
| History of AKI | 1.9 [1.21–2.91] | 4.03 e-3* | 1.2 [0.74–1.97] | 0.43 |
| History of ADRs | Reference | Reference | Reference | Reference |
| No history of ADRs | Reference | Reference | Reference | Reference |
| History of ADRs | 1.8 [1.24–2.57] | 1.75 e-3* | 1.4 [0.91–2.05] | 0.12 |

Note: Statistically significant differences are shown in bold type.
Abbreviations: ADRs, adverse drug reactions; AKI, acute kidney injury; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; OR, odds ratio.
*Adjusted for variables with P < 0.2 in a univariate analysis or contextual interest.
*bAccording to the patients’ EMRs.
*Statistically significant.
and excretion and the greater accumulation of parent risk of ADRs, due to impairments in drug metabolism. Moreover, patients with a low GFR have an elevated risk of AKI and to slow down the kidneys ability to recover. A history of CKD was a consistent risk factor for drug-induced AKI overall and for the CA-AKI and HA-AKI subgroups. The relationship between CKD and AKI has already been highlighted by several studies. Firstly, CKD is known to predispose or sensitize patients to AKI and to slow down the kidneys’ ability to recover; in a large cohort of patients with CKD, we highlighted the high prevalence of ADRs when drug-induced AKI had been the first reported serious ADR. Secondly, AKI may contribute to the development and progression of CKD through the failure of self-regulation, abnormal vasodilation, sensitivity to antihypertensive drugs, and the occurrence of ADRs. Moreover, patients with a low GFR have an elevated risk of ADRs, due to impairments in drug metabolism and excretion and the greater accumulation of parent drugs and their metabolites. Surprisingly, a history of AKI was not found to be a risk factor for drug-induced AKI in our multivariate analysis—even though AKI’s harmful effects on kidney recovery are well described. Likewise, history of AKI was not a risk factor for CA-AKI or HA-AKI.

In the literature, drug-induced AKIs are often compared with non-drug-induced AKIs. Few studies have described the influence of drugs on AKI outcomes. Alkhunaizi et al. showed that patients with drug-induced AKI were younger, more likely to be female and more likely to have CKD than those with non-drug-induced AKI but did not report on the outcomes. Here, we compared outcomes in drug-induced AKI versus non-drug-induced AKI. Drug-induced AKIs were more likely to have a favorable outcome but were also more likely to lead to the onset or progression of CKD. Drug-induced AKIs were more likely to be managed in a nephrology department. This might be due to the higher prevalence of CKD in the drug-induced AKI group (40.4%) than in the non-drug-induced AKI group (23.8%). Furthermore, the majority of AKIs analyzed here were not managed in a nephrology department—probably because AKI is often multifactorial and is associated with other pathologies, such as sepsis and heart failure.

The length of stay was shorter for drug-induced AKIs than for non-drug-induced AKIs. A deeper understanding of these data might help to improve the management of drug-induced AKI and to preserve kidney function.

Our study had a number of strengths. Firstly, the AKI cases were selected rigorously by applying the KDIGO guidelines (an international benchmark) and by screening the EMRs. Secondly, all ADRs were fully reviewed by a pharmacovigilance specialist. Thirdly, the consecutive patient recruitment and the large numbers of included AKIs enabled us to describe drug-induced events and evaluate them according to where they occurred (i.e., in hospital or in the community). To the best of our knowledge, the present study is the first to have determined the proportions of HA-AKI and CA-AKIs in a cohort of patients with drug-induced AKIs and to have determined the affected patients’ characteristics and outcomes.

Our study had some limitations. Firstly, our single-center study was conducted in a university hospital in northern France, and so our findings might reflect the prescribing habits of our local general practitioners and the hospital’s clinicians. However, as shown by the literature data, we expect the clinical characteristics of patients with drug-induced AKI to be much the same in France as in other countries. Secondly, we focused on a specific cause of AKI, even though the latter it is often multifactorial. Hence, it would be useful to determine whether certain causes are more likely than others to be associated with poorer outcomes. Thirdly, we did not collect information on the use of over-the-counter drugs or self-medication; this might have led us to underestimate exposure to certain drugs such as NSAIDs. Indeed, analgesics like NSAIDs are frequently used for self-medication, and the continuous use of NSAID (alone or combined with other drugs) for pain relief over long periods of time is associated with the development of progressive kidney disease or AKI. Information on self-medication rarely recorded in hospital discharge summary databases like the PMSI and is not systematically recorded in EMRs. Furthermore, AKI cases were evaluated by a single adjudicator; a manually review of all EMRs was a time-consuming process that prevented a second evaluation. We did not have access to urine output, which could have led to an underestimation of AKI cases. However, our algorithm is known to be highly specific for AKI and our aim was not to calculate the prevalence of AKI. Lastly, patients were not followed up after discharge from hospital (preventing us from evaluating the long-term outcomes associated with drug-induced AKI), and our study period was short (6 months).
Despite these limitations, our large, comparative study of CA-AKI and HA-AKI provided a better understanding of the epidemiology, risk factors, course, and outcomes for these two specific types of drug-induced AKI.

5 | CONCLUSION

Drug-induced AKIs account for a large (and possibly underestimated) proportion of community- and hospital-acquired AKIs. The serious consequences of AKI on kidney and the potential for further ADRs mean that efforts should be made to optimize treatment and understanding all the risk factors in specific populations (such as those with community- or hospital-acquired AKIs). Indeed, we found some differences between the CA-AKI and HA-AKI subgroups with regard to patient characteristics and outcomes. Since a large proportion of drug-induced AKIs are avoidable, the close monitoring of female patients with multiple comorbidities (particularly CKD and a history of ADRs) might limit the risk of drug-induced AKI and thus have a positive impact on healthcare costs and patient care. To study AKI in more depth and improve the quality of the data, future research might usefully include a longer follow-up period, a larger, multicentre cohort, the use of natural language processing (to avoid time-consuming reviews), and a pharmacovigilance database.

ACKNOWLEDGEMENT

This research did not receive any specific funding from agencies in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

ETHICS APPROVAL

The IRA-PMSI study’s objectives and procedures were approved by an independent ethics committee (CPP Nord Ouest II, Amiens, France; reference: RCB 2020-A00556-33).

PATIENT CONSENT

In line with the French legislation on non-interventional studies, patients were provided with information about the study and were free to refuse to participate.

CLINICAL TRIAL REGISTRATION

The study was registered at ClinicalTrials.gov (NCT04923750).

AUTHOR CONTRIBUTIONS

AR was a major contributor to the acquisition, analysis, and interpretation of the data; drafted the article; and revised it critically for important intellectual content. GC and KM were the major contributors to analysis and interpretation of the data and revised the article critically for important intellectual content. VG and SL were the major contributors to the study conception and design and acquisition, analysis, and interpretation of the data; drafted the article, and revised it critically for important intellectual content. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID

Amayelle Rey @ https://orcid.org/0000-0002-9152-3776

REFERENCES

1. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756-766.
2. Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58-66.
3. Venkatachalam MA, Weinberg JM, Kriz W, et al. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765-1776.
4. Nie S, Feng Z, Tang L, et al. Risk factor analysis for AKI including laboratory indicators: a nationwide multicenter study of hospitalized patients. Kidney Blood Press Res. 2017;42(5):761-773.
5. Catin-Ceba R, Kashiouris M, Platani M, Kor DJ, Gajic O, Casey ET. Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Res Pract. 2012;2012:1-15.
6. Perez-Ruiz F. Treatment with allopurinol is associated with lower risk of acute kidney injury in patients with gout: a retrospective analysis of a nested cohort. Rheumatol Ther. 2017;4(2):419-425.
7. Rey A, Gras-Champel V, Balcaen T, Choukroun G, Masmoudi K, Liabeuf S. Use of a hospital administrative database to identify and characterize community-acquired, hospital-acquired and drug-induced acute kidney injury. J Nephrol. Published Online October. 2021.
8. Robert L, Ficheur G, Gautier S, et al. Community-acquired acute kidney injury induced by drugs in older patients: a multifactorial event. Clin Interv Aging. 2019;14:2105-2113.
9. Moore PK, Hsu RK, Liu KD. Management of acute kidney injury: core curriculum 2018. Am J Kidney Dis. 2018;72(1):136-148.
10. Pierson-Marchandise M, Gras V, Moragny J, et al. The drugs that mostly frequently induce acute kidney injury: a case–noncase study of a pharmacovigilance database: Drug-induced acute kidney injury. Br J Clin Pharmacol. 2017;83(6):1341-1349.
11. Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury: A Focus on Risk Assessment for Prevention. Crit Care Clin. 2015;31(4):675-684.
12. Jacobs F, Brivet F. Épidémiologie et pronostic des insuffisances rénales aiguës en réanimation. Réanimation. 2005;14(6):472-482.
13. Khajavi RA, Mohebbat R, Hosseinian S. Drug-induced nephrotoxicity and medicinal plants. Iran J Kidney Dis. 2017;11(3):169-179.
14. Handler SM, Cheung PW, Culley CM, et al. Determining the incidence of drug-associated acute kidney injury in nursing home residents. J Am Med Dir Assoc. 2014;15(10):719-724.
15. Ghane SF. Drug-induced renal disorders. J Renal Inj Prev 2015; 4(3):57-60.
COMMUNITY AND HOSPITAL-ACQUIRED DRUG-INDUCED AKI

16. Soulie M, Stephan Y, Nicol L. Poster abstracts. Fundam Clin Pharmacol. 2021;35(5):89-207.

17. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009;4(7):1275-1283.

18. Khaliti H, Bairami S, Kargar M. Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome. Acta Med Iran. 2013;51(12):871-878.

19. Wu H, Huang J. Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies. Curr Drug Metab. 2018;19(7):559-567.

20. Uchino S. The epidemiology of acute renal failure in the world. Curr Opin Crit Care. 2006;12(6):538-543.

21. Liu C, Yan S, Wang Y, et al. Drug-induced hospital-acquired acute kidney injury in china: a multicenter cross-sectional survey. Kidney Dis Published online September. 2020;30:1-13.

22. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.

23. Khan LM, Al-Harthi SE, Osman AMM, et al. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J. 2016;24(4):485-493.

24. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2020.

25. Rolland AL, Garnier AS, Meunier K, et al. Drug-induced acute kidney injury: a study from the french medical administrative and the French National Pharmacovigilance Databases using capture-recapture method. J Clin Med. 2021;10(2):168-179.

26. Hoste EAJ, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411-1423.

27. Khan S, Loi V, Rosner MH. Drug-induced kidney injury in the elderly. Drugs Aging. 2017;34(10):729-741.

28. Pascual J, Orofino L, Liao F, et al. Incidence and prognosis of acute renal failure in older patients. J Am Geriatr Soc. 1990;38(1):25-30.

29. Rosner MH. Acute kidney injury in the elderly. Clin Geriatr Med. 2013;29(3):565-578.

30. Patschan D, Patschan S, Buschmann I, Ritter O. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res. 2019;44(4):457-464.

31. Che ML, Yan YC, Zhang Y, et al. Analysis of drug-induced acute renal failure in Shanghai. Zhonghua Yi Xue Za Zhi. 2009;89(11):744-749.

32. Jannot AS, Burgun A, Thervet E, et al. The diagnosis-wide landscape of hospital-acquired AKI. Clin J Am Soc Nephrol CJASN. 2017;12(6):874-884.

33. Chandiramani R, Cao D, Nicolas J, Mehran R. Contrast-induced acute kidney injury. Cardiovasc Interv Ther. 2020;35(3):209-217.

34. Holditch SJ, Brown CN, Lombardi AM, et al. Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury. Int J Mol Sci. 2019;20(12):3011-3035.

35. Angamo M.T., Curtain C.M., Chalmers L., et al. Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: a prospective cross-sectional study. Ramagopalvan SV, Ed PLoS ONE 2017;12(10):e0186631.

36. Wu X, Zhang W, Ren H, Chen X, Xie J, Chen N. Diuretics associated acute kidney injury: clinical and pathological analysis. Ren Fail. 2014;36(7):1051-1055.

37. van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018;28(7):2856-2869.

38. Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J Transl Med. 2020;18(1):400-434.

39. Yu Y, Chen J, Li D, et al. Systematic analysis of adverse event reports for sex differences in adverse drug events. Sci Rep. 2016;6(1):24955-24963.

40. Moyer AM, Matey ET, Miller VM. Individualized medicine: sex, hormones, genetics, and adverse drug reactions. Pharmacol Res Perspect. 2019;7(6).

41. Ikeda M, SWide T, Vayl A, Lahm T, Anderson S, Hutchens MP. Estrogen administered after cardiac arrest and cardiopulmonary resuscitation ameliorates acute kidney injury in a sex- and age-specific manner. Crit Care. 2015;19(1):332-345.

42. Watson S, Caster O, Rochon PA, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17:100188.

43. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German University Hospitals. Drug Saf. 2008;31(9):789-798.

44. Perazella MA. Drug-induced nephropathy: an update. Expert Opin Drug Saf. 2005;4(4):689-706.

45. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60(2):804-817.

46. Wai AO, Lo AM, Abdo A, et al. Vancomycin-induced acute interstitial nephritis. Ann Pharmacother. 1998;32(11):1160-1164.

47. He L, Wei Q, Liu J, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92(5):1071-1083.

48. Laville SM, Gras-Champel V, Moragny J, et al. Adverse drug reactions in patients with CKD. Clin J Am Soc Nephrol. 2020;15(8):1090-1102.

49. Baker M, Perazella MA. NSAIDs in CKD: are they safe? Am J Kidney Dis. 2020;76(4):546-557.

50. Alkhunaizi AM, Al SM. In-hospital acute kidney injury. East Mediterr Health J. 2020;26(8):967-970.

51. Faqihi AHMA, Sayed SF. Self-medication practice with analgesics (NSAIDs and acetaminophen), and antibiotics among nurses during half a century. Acta Medica East. 2015;36(7):1051-1055.

52. Ramagopalan SV, Rey A, Gras-Champel V, Choukroun G, Masmoudi K, Liabeuf S. Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries. Fundam Clin Pharmacol. 2022;36(4):750-761. doi: 10.1111/fcp.12758

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.